D2M Biotherapeutics, a tumor immunological drug developer, recently completed a Pre-A round of US$10 million in financing led by Apricot Capital (Shanghai).
D2M Biotherapeutics focuses on the development of a new generation of tumor immune drugs driven by genomics.
It aims to expand the potential of immunotherapy by targeting genetically verified disease-related immune pathways to find high-quality targets with a higher probability of success.
According to incomplete statistics, D2M Biotherapeutics has a total of 46 financings this year.
According to reports, this round of investor Apricot Capital (Shanghai) was established in 2015. The management team is composed of more than 20 professionals and consultants with rich investment experience in the medical and health field. Their professional background covers life sciences, medicine, finance and law. .
Apricot Capital (Shanghai) focuses on investing in outstanding companies in the early and growth stages of the medical and health industry. Investment projects cover biopharmaceuticals, life sciences, medical devices, medical services and diagnostics.
Its invested companies include TopAlliance (Junshi Pharma), Ambrx, SinoMab BioScience Limited, UniCAR, Sinovent, and Tissue Bank, Shanghai MicroPort CardioFlow Medtech, Fountain Medical Development (or FMD China), Pharmcube and many other star companies.
Its return on investment leads in China's venture capital industry.
Apricot Capital has recently invested in companies such as Peking Jabrehoo Med Tech and Bellen Ningyuan Group (Bellen).